{"nct_id":"NCT03623243","title":"Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients","status":"COMPLETED","status_verified_date":"2024-06","start_date":"2019-02-14","start_date_type":"ACTUAL","primary_completion_date":"2022-07-06","primary_completion_date_type":"ACTUAL","completion_date":"2022-07-06","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["NVS"]}